Physician profile
Libbe B Marquez
NPI 1336719400
$2,186.51
in general payments reported to CMS, 2019-2025
25 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Clinical Nurse Specialist provider received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $352 · 2023: $805 · 2024: $517 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.42 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $642.45 | 2021-2025 | Tagrisso, Calquence, Lynparza |
| Astellas Pharma US INC | $287.00 | 2022-2023 | |
| Janssen Biotech, INC. | $228.57 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $130.98 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $128.91 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $117.20 | 2023 | Opdivo |
| Daiichi Sankyo INC. | $85.04 | 2022-2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $80.15 | 2023-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $66.60 | 2022-2025 | Fotivda |
| Seagen INC. | $54.82 | 2021-2023 | Adcetris |
| Genmab U.S., INC. | $53.06 | 2023-2024 | Epkinly, Tivdak |
| Genzyme Corporation | $46.15 | 2021-2022 | |
| Sobi, INC | $31.83 | 2023 | |
| Amgen INC. | $24.61 | 2022 | |
| Gilead Sciences, INC. | $23.90 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $22.86 | 2023 | Besremi |
| Novo Nordisk INC | $21.58 | 2022 | |
| Incyte Corporation | $21.47 | 2025 | Monjuvi |
| Geron Corporation | $20.44 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $19.38 | 2024 | Pyrukynd |
| Beigene USA, INC. | $17.87 | 2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $17.14 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.32 | 2025 | Fruzaqla |
| Puma Biotechnology, INC. | $15.64 | 2023 | |
| Lilly USA, LLC | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libbe Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.